期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

厄洛替尼致肺癌患者相关性皮疹的临床治疗 被引量：5

Clinical treatment of Erlotinib treatment-related skin rash in patients with non-small cell lung cancer
原文传递
导出
摘要 目的探讨厄洛替尼所致肺癌患者相关性皮疹的特点,及其临床诊疗要点。方法 观察临床确诊的20例非小细胞肺癌(NSCLC)患者口服厄洛替尼后出现的药物相关性皮疹,并进行相应的诊疗,评估皮疹的发生情况以及意义。结果 20例患者不同程度出现1～2级皮疹反应,无3级以上皮疹反应发生,患者耐受性、依从性满意。结论 厄洛替尼相关性皮疹是常见的不良反应,直接干扰了患者的正常治疗,严重影响患者生活质量甚至可导致治疗中断。有效地评估和治疗患者皮疹反应具有积极的意义。 Objective To observe the features of Erlotinib treatment-related skin rash and analyze the key points of nursing and treatment. Methods To observe medicine-related skin rash in the 20 patients with non-small cell lung cancer （NSCLC） after they took Erlotinib, to treat accordingly and evaluate its effect and significance. Results Level one to level two of skin rash turned up in the 20 patients, no level three. Endurance and dependence of patient were good. Conclusions Erlotinib-related skin rash is the common adverse effect in patients, it interfere with the normal treatment directly and effect on the quality of life seriously, even leading to the interruption of treatment. Therefore, it is significant that effective assessment and treatment in patients with rash.
作者 高文斌 韩传军 张晓晨 刘思思 韩佩妍
机构地区 大连大学附属中山医院肿瘤科 大连大学
出处 《中华肺部疾病杂志（电子版）》 CAS 2012年第4期15-17,共3页 Chinese Journal of Lung Diseases(Electronic Edition)
关键词 支气管肺癌 抗肿瘤药 厄洛替尼 药疹 Bronchial carcinoma Antineoplastic agents Erlotinib Drug eruptions
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1Herbst RS,Langer CJ. Epidermal growth factor receptors as a target for cancer treatment:the emerging role of IMC-C225 in the treatment of lung,and head and neck cancers[J].Seminars in Oncology,2002,(Suppl 4):27-36.
  • 2Perez-Soier R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer[J].Clinical Lung Cancer,2006,(Suppl):S7-S14.
  • 3Paz-ares L,Sanchez JM,Garcia-Velasco A. A prospecitive phase Ⅱtrial of erlotinib in advanced non-small cell lung cell (NSCLC) patients(p) with mutation in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)[J].Journal of Clinical Oncology,2006,(18s):369-375.
  • 4Perez-Soier R,Chachoua A,Hammond LA. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer[J].Journal of Clinical Oncology,2004,(16):3238-3247.doi:10.2176/nmc.50.179.
  • 5Herbst RS,Prager D,Hermann R. TRIBUTE:a phase Ⅲ trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non small cell lung cancer[J].Journal of Clinical Oncology,2005,(25):5892-5899.doi:10.1200/JCO.2005.02.840.
  • 6Soulieres D,Senzer NN,Vokes EE. Multicenter phase Ⅱ study of erlotinib.an oral epidermal growth factor receptor tyrosine kinas inhibitor,in patients with recurrent or metastatic squamous cell cancer of the head and neck[J].Journal of Clinical Oncology,2004,(01):77-85.doi:10.1016/j.fishres.2010.02.007.
  • 7Hidalgo M,Bloedow D. Pharmacokinetics and pharmacodynamics:maximizing the clinical potential of erlotinib (Tarceva)[J].Seminars in Oncology,2003,(3 Suppl 7):25-33.
  • 8Malik SN,Siu LL,Rowinsky EK. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients[J].Clinical Cancer Research,2003,(07):2478-2486.
  • 9Lacouture ME. Mechainisms of cutancous toxicities to EGFR inhibitors[J].Nature Reviews Cancer,2006,(10):803-812.doi:10.1038/nrc1970.
  • 10Woodworth CD,Micheal E,Marker D. Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation,apoptosis,and cell attachment[J].Molecular Cancer Therapeutics,2005,(04):650-658.doi:10.1097/CCM.0b013e3181b9e302.

二级参考文献11

  • 1Herbst RS, Langer CJ. Epidemal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung, and head and neck cancers. Semin Oncol, 2002,29 (1 Suppl 4) :27-36.
  • 2Perez-Soier R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer, 2006,8(Suppl) :S7- S14.
  • 3Paz- ares L, Sanchez JM, Garcia- Velasco A, et al. A prospecitive phase II trial of erlotinib in advanced non-small cell lung cell (NSCLC) patients(p) with mutation in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol, 2006,24(18s) :369-375.
  • 4Perez-Soier R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small- cell lung cancer. J Clin Oncol, 2004, 22(16) :3238-3247.
  • 5Herbst RS, Prager D, Hermann R, et al. TRIBUTE : a phase Ⅲ trial of erlotinib hydrochloride ( OSI-774 ) combined with carboplatin and paclitaxel chemotherapy in advanced non small cell lung cancer. J Clin Oneol, 2005, 23(25) :5892-5899.
  • 6Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase Ⅱ study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol, 2004, 22( 1 ) :77-85.
  • 7Hidalgo M, Bloedow D. Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of erlotinib (Tarceva). Semin Oncol, 2003, 30(3 Suppl 7):25-33.
  • 8Malik SN, Siu LL, Rowinsky EK, et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res, 2003, 9 ( 7 ) : 2478- 2486.
  • 9Lacouture ME. Mechainisms of cutancous toxicities to EGFR inhibitors. Nat Rev Cancer, 2006, 6 (10) : 803-812.
  • 10Woodworth CD, Micheal E, Marker D, et al. Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol Cancer Ther, 2005, 4(4) :650-658.

同被引文献62

引证文献5

二级引证文献31

中华肺部疾病杂志（电子版）
2012年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部